BioBlast Pharma
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
37 Dereh Menachem Begin St Fl 15, Tel Av...Phone Number
+972 722409060Website
www.bioblastpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BioBlast Pharma
Bioblast Pharmaceuticals is a reputable company specializing in biotechnology research and the development of clinically approved treatment solutions for patients with various genetic diseases. Established in 2012, the company focuses on creating a diverse portfolio of online pharmacy medications aimed at addressing rare diseases that lack approved cures. Bioblast has successfully developed specific therapeutic methods to enhance understanding of pathogenic processes and related diseases. The company ensures that its medications target specific diseases caused by similar pathogens.Explore more
BioBlast Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioBlast Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BioBlast Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if BioBlast Pharma is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if BioBlast Pharma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on BioBlast Pharma recently announced quarterly report
BioBlast Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BioBlast Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at BioBlast Pharma
Funding: Get notified immidiatlly once BioBlast Pharma has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
BioBlast Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioBlast Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioBlast Pharma.
BioBlast Pharma financials insights
Gather financial insights about BioBlast Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$35.2M
BioBlast Pharma Tech Stack
A closer look at the technologies used by BioBlast Pharma
See more technologies
BioBlast Pharma News & Media
Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma
Diversifies Seelos’ pipeline in rare diseasesBioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics
Tel Aviv, Israel, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. ( Nasdaq: ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced the sale of its Trehalose clinical development programs (including its advanced phase 2 clinical program of Trehalose to treat Oculoharyngeal Muscular Dystrophy (OPMD) to Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company. Under the terms of the agreement, Seelos will pay Bioblast a paymenBioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome
Tel Aviv, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast”), a clinical-stage, orphan disease-focused biotechnology company, and Team Sanfilippo (“TSF”), a nonprofit medical research foundation founded by parents of children with Sanfilippo Syndrome today announced a clinical collaboration to evaluate the safety and efficacy of Bioblast’s proprietary Trehalose solution for the treatment of patients with Sanfilippo syndrome.Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance
Tel Aviv, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqCM: ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that Nasdaq has determined that Bioblast’s stockholders’ equity does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioBlast Pharma
Sign Up For FreeTo access detailed company insights
Bioblast Pharmaceuticals is a reputable company specializing in biotechnology research and the development of clinically approved treatment solutions for patients with various genetic diseases. Established in 2012, the company focuses on creating a diverse portfolio of online pharmacy medications aimed at addressing rare diseases that lack approved... Read More
